Jupiter Neurosciences (NASDAQ:JUNS) Announces Earnings Results

Jupiter Neurosciences (NASDAQ:JUNS) released its quarterly earnings data on Friday. The company reported ($4.08) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.02 million for the quarter.

Jupiter Neurosciences Trading Down 12.7%

Shares of JUNS stock traded down $0.76 during trading hours on Friday, reaching $5.24. The stock had a trading volume of 105,488 shares, compared to its average volume of 82,146. The stock’s fifty day simple moving average is $12.93 and its 200 day simple moving average is $25.41. Jupiter Neurosciences has a 12 month low of $4.56 and a 12 month high of $137.96. The firm has a market capitalization of $4.03 million, a PE ratio of -0.26 and a beta of 1.98.

Analyst Ratings Changes

Several research firms have issued reports on JUNS. Wall Street Zen downgraded Jupiter Neurosciences to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of Jupiter Neurosciences

Several institutional investors and hedge funds have recently bought and sold shares of JUNS. Allen Capital Group LLC bought a new position in Jupiter Neurosciences in the 4th quarter valued at $31,000. Yorkville Advisors Global LP bought a new position in shares of Jupiter Neurosciences in the fourth quarter worth $135,000. Geode Capital Management LLC raised its position in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after buying an additional 28,826 shares in the last quarter. Finally, Vestor Capital LLC raised its position in shares of Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after buying an additional 970,314 shares in the last quarter.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.